136 related articles for article (PubMed ID: 6414690)
1. Ifosfamide, mesna and vincristine in paediatric oncology.
de Kraker J; Voûte PA
Cancer Treat Rev; 1983 Sep; 10 Suppl A():165-6. PubMed ID: 6414690
[No Abstract] [Full Text] [Related]
2. Irreversible encephalopathy with ifosfamide/mesna.
Salloum E; Flamant F; Ghosn M; Taleb N; Akatchereian C
J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
[No Abstract] [Full Text] [Related]
3. Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
Matthiessen W; Stempinski E; Göbel D; Thalmann U
Cancer Treat Rev; 1983 Sep; 10 Suppl A():121-3. PubMed ID: 6414688
[No Abstract] [Full Text] [Related]
4. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
5. Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
Cantwell BM; Harris AL; Bozzino JM
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S29. PubMed ID: 3028660
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.
Dorr RT
Semin Oncol; 1990 Aug; 17(4 Suppl 7):2-5. PubMed ID: 2116668
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Sanchiz F; Milla A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
[TBL] [Abstract][Full Text] [Related]
8. Full-dose ifosfamide can be safely administered to outpatients.
Meazza C; Bisogno G; Casanova M; Zanetti I; Carli M; Ferrari A
Pediatr Blood Cancer; 2008 Feb; 50(2):375-8. PubMed ID: 16847930
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cantwell BM; Carmichael J; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide/mesna encephalopathy.
McCallum AK
Lancet; 1987 Apr; 1(8539):987. PubMed ID: 2882385
[No Abstract] [Full Text] [Related]
11. Severe renal failure following high-dose ifosfamide and mesna.
Willemse PH; de Jong PE; Elema JD; Mulder NH
Cancer Chemother Pharmacol; 1989; 23(5):329-30. PubMed ID: 2495864
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer.
Focan C; Boossy J; Focan-Henrard D; Reginster M; Claessens JJ
Cancer Chemother Pharmacol; 1989; 23(3):192-3. PubMed ID: 2493996
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide/mesna and hematuria.
Pratt CB; Goren MP
Cancer Treat Rep; 1987 Nov; 71(11):1124-5. PubMed ID: 3119210
[No Abstract] [Full Text] [Related]
14. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Pratt CB; Douglass EC; Etcubanas E; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
Semin Oncol; 1989 Feb; 16(1 Suppl 3):51-5. PubMed ID: 2495567
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Klein HO; Wickramanayake PD; Coerper C; Christian E; Pohl J; Brock N
Cancer Treat Rev; 1983 Sep; 10 Suppl A():167-73. PubMed ID: 6414691
[No Abstract] [Full Text] [Related]
16. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
Katz A; Epelman S; Anelli A; Gorender EF; Cruz SM; Oliveira RM; Marques LA
J Cancer Res Clin Oncol; 1995; 121(2):128-31. PubMed ID: 7883776
[TBL] [Abstract][Full Text] [Related]
19. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
20. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
